Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog. This rapid-acting insulin ...

Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

The shares of the prominent pharmaceutical company gained up to 4 percent in today's trading session after the company ...

Biocon’s arm won FDA approval for a diabetes drug, while Zydus Life also got the green light for its pain relief drug. Stocktwits data shows a sharp shift in retail sentiment to bullish on both pharma ...

Indian equity markets snapped a four-session losing streak to end in positive territory on Tuesday, driven by gains in auto ...

The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

Biocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin ...

Biocon share price today rose 3% after Biocon Biologics received US FDA approval for diabetes drug Kirsty, the first interchangeable biosimilar to NovoLog in the US. Get latest updates on Biocon ...

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...